Targovax to present at forthcoming conferences

OSLO, Norway, May 31, 2016 -- Targovax, a clinical stage immuno-oncology company, developing targeted immunotherapy treatments for cancer patients, announces that members of its senior management team will participate in the following life sciences and investor conferences:

Redeye Investor Forum
Stockholm, 1 June 2016
Participants: Magnus Jäderberg (CMO)
Presentation time: 18:00
Venue: Redeye HQ, Mäster Samuelsgatan 42, Stockholm

Redeye Investor Forum
Västerås, 7 June 2016
Participants: Magnus Jäderberg (CMO)
Presentation time: 19:30
Venue: Elite Stadshotellet, Stora Torget, Västerås

Småbolagsdagen 2016
Stockholm, 13 June 2016
Participants: Gunnar Gårdemyr (CEO)
Presentation time: 17:00 (Room 2 - Life Science)
Venue: Sheraton Stockholm Hotel, Tegelbackan 6, Stockholm

BIO International Convention
San Francisco, 6-9 June 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP Business Development)

The presentations will be available to download at www.targovax.com following the event.

For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79

Email: [email protected]

Øystein Soug, CFO
Phone: +47 906 56 525
Email: [email protected]

Arming the patient's immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.

ONCOS - 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells.

TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.

HUG#2016583